This is the second of two articles written by Caroline Lock and Spencer Marsh at Only Medics Recruitment Ltd. In the last edition they looked at Recruitment 2010 and in this article they discuss Career Planning 2010.
For over 75 years now, numerous Democratic Congressmen â€“ and indeed several Presidents â€“ have tried to pass something remotely resembling meaningful healthcare reform. For 75 years, they have failed. Back in 1993, Bill and Hillary Clintonâ€™s failed â€˜HillaryCareâ€™ died with a whimper in the Senate and Mrs. Clinton was denied her chance at a second attempt by Mr. Obama in the Democratic primaries.
â€˜You really need some more experienceâ€™. Perhaps the most ubiquitous phrase in modern day recruitment, thousands of graduates are now at the mercy of this one requirement as increasing competition in the job market leads to rising standards. Perhaps twenty, or even ten years ago, an undergraduate degree and a forceful sense of charisma might well have been enough to net you your first role in an industry.
Keynes called it an â€˜inducement to investâ€™. In this instance, the most recent financial crisis has called for many of the same approaches used in the 1930s to stimulate the economy and bring industries back to their feet. Today more than ever, we realize that education is one of the most decisive facets of any successful stimulus.
At what point does a conflict of interests occur? Last year â€“ and for many years before that â€“ U.S. drugs companies paid out tens of millions of dollars in payments and gifts to physicians and academics. Earlier this year, the Pharmaceutical and Research Manufacturers of America (PhRMA) released a revised, and somewhat toughened, code of practice.
Over the past year or so, the system for issuing VISAs and work permits in the UK has changed dramatically. A knowledge of the practical implications of the new system will be vital for anyone hoping to bring their skills to the pharmaceutical industry in this country
The phrase Halcyon days is a literary commonplace in the English language English language and culture, signifying ideals of prosperity, bonhomie, joy, liberation, or tranquility. I can testify to experiencing all these sentiments having worked in Clinical R&D for nearing 30 years. I'm not so certain we'll ever return to the same again though.
Ann Maloney BSc FICR
I recently surveyed a range of pharmaceutical HR managers and recruiters to find out what they consider to be the worst errors you can make on your CV when applying for a pharma job. The results were quite surprising and funny at times, so I have compiled the following 10 point checklist to help you with your CV.
The craving for cheap drugs has never been greater. For those patients and policymakers in developing countries, the existence of parallel imports is less a concern than a blessing. Yet for pharmaceutical companies themselves, there is the concern that an increasing trade in parallel imports would severely damage research-intensive activities and ultimately slow down the development of the very same drugs that are being traded in â€˜greyâ€™ markets today.
In this edition of StrategicEdge, CBR Pharma Insights discusses some of the recent rulings by the Indian courts and their impact on the pharmaceutical industry's increasing interest in India.
CBR Pharma Insights
Ever since the H1N1 virus first came onto the world map in April, â€˜Whereâ€™s the vaccine?â€™ has been the cardinal question on everybodyâ€™s lips. As world governments scrambled to control the outbreak, supranational bodies such as the World Health Organization (WHO) threw themselves at the task of producing weekly updates for a virus which we originally knew very little about.
It is frightening because no one knows what's causing it, said a 28-year old law student who went to the St. Mark's Clinic in Greenwich Village last week complaining of swollen glands, thought to be one early symptom of the disease. Every week a new theory comes out about how you're going to spread it. - The New York Times , August 8th 1982.
A meta-analysis of the CRYSTAL and OPUS studies involving 845 patients with metastatic colorectal cancer (mCRC) tumours displaying the wild-type KRAS gene, has revealed first-line treatment with Erbitux (cetuximab) and FOLFOX4 or FOLFIRI chemotherapy significantly extends overall survival.
Olwen Glynn Owen
Hardly a day goes by without a new report, today AT Kearney, last week Roland Berger and before them IMS and PWC warning of a gloomy future for pharmaceutical companies and saying that they must change their ways.
Paul Dixey, Managing Partner, BlueLight Partners
In the eyes of many graduates, the economic recession has brought a new-found negativity to the job market. Thankfully, the climate is probably less dire than the situation sometimes imagined.
More than half of schizophrenia patients are expected to relapse within two years if untreated and 4 out of 5 within five years, according to experts. Antipsychotics can reduce the relapse rate so long as patients continue on treatment. However, adherence is notoriously poor. A new antippsychotic â€“ asenapine â€“ shows promise of being effective and better tolerated.
Olwen Glynn Owen
Max Golby, Freelance Journalist, takes a look at the history of the e-Detailing market, considers what the e-Detail of the future might look like and asks what marketing departments can learn from an academic analysis of the instrument.
As Capitol Hill readies itself for the August Recess, and as President Barack Obama demands that a bill reach his desk in the Oval Office by October, healthcare reform still finds itself in more-or-less the same quagmire as it did in 1993. We take a look at the chances of comprehensive reform this year and tackle the nitty-gritty of one of the most complex and polarising issues of Washington politics today.
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her